Short answer
Compass Therapeutics, Inc. (CMPX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$14M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$14M
- −36.1% YoY · +28.3% QoQ
- EPS (diluted)
- −$0.08
- +0.0% YoY · +42.9% QoQ
Source: XBRL data from the Compass Therapeutics, Inc. (CMPX) Q3 2025 10-Q on SEC EDGAR. USD.
Compass Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No quarterly product revenue; net loss $14.3M vs $10.5M YoY
- Operating margin -15,817% vs -12,239% YoY
- CTX-10726 highest R&D spending $4.6M; tovecimig lowest $3.3M
- Cash, equivalents and marketable securities $220M; operating cash used $35.9M
- Cash runway into 2028; BTC survival and progression data expected late Q1 2026
Risk Factors
- Newly added global-conditions risk triggered by economic uncertainty, tariffs, inflation, and financial-market dislocations
- Newly added drug-pricing risk triggered by Executive Orders 14273 and 14297 issued April 15 and May 12, 2025
- Regulatory risk: most-favored-nation pricing targets could reduce reimbursement if products gain approval
- Legal risk: prior Most Favored Nation pricing rule faced judicial injunction before August 2021 rescission
- Carried-forward risks: no material changes to 2024 Form 10-K risk factors beyond additions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Compass Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.